Compare Novartis with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs ABBOTT INDIA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS ABBOTT INDIA NOVARTIS/
ABBOTT INDIA
 
P/E (TTM) x 512.7 44.7 1,146.5% View Chart
P/BV x 29.7 12.8 232.2% View Chart
Dividend Yield % 1.5 0.5 285.2%  

Financials

 NOVARTIS   ABBOTT INDIA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
ABBOTT INDIA
Mar-18
NOVARTIS/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs7586,110 12.4%   
Low Rs5793,996 14.5%   
Sales per share (Unadj.) Rs228.41,552.2 14.7%  
Earnings per share (Unadj.) Rs31.7188.8 16.8%  
Cash flow per share (Unadj.) Rs32.8196.4 16.7%  
Dividends per share (Unadj.) Rs10.0055.00 18.2%  
Dividend yield (eoy) %1.51.1 137.4%  
Book value per share (Unadj.) Rs297.1796.6 37.3%  
Shares outstanding (eoy) m24.6921.25 116.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.93.3 89.9%   
Avg P/E ratio x21.126.8 78.7%  
P/CF ratio (eoy) x20.425.7 79.3%  
Price / Book Value ratio x2.26.3 35.5%  
Dividend payout %31.529.1 108.2%   
Avg Mkt Cap Rs m16,505107,376 15.4%   
No. of employees `0000.73.3 20.1%   
Total wages/salary Rs m1,4453,937 36.7%   
Avg. sales/employee Rs Th8,441.39,929.3 85.0%   
Avg. wages/employee Rs Th2,163.61,185.1 182.6%   
Avg. net profit/employee Rs Th1,173.11,207.7 97.1%   
INCOME DATA
Net Sales Rs m5,63932,985 17.1%  
Other income Rs m1,7181,170 146.9%   
Total revenues Rs m7,35734,155 21.5%   
Gross profit Rs m-635,245 -1.2%  
Depreciation Rs m25162 15.6%   
Interest Rs m5538 144.8%   
Profit before tax Rs m1,5756,215 25.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7922,203 35.9%   
Profit after tax Rs m7844,012 19.5%  
Gross profit margin %-1.115.9 -7.0%  
Effective tax rate %50.335.4 141.8%   
Net profit margin %13.912.2 114.2%  
BALANCE SHEET DATA
Current assets Rs m9,52222,655 42.0%   
Current liabilities Rs m3,2966,681 49.3%   
Net working cap to sales %110.448.4 228.0%  
Current ratio x2.93.4 85.2%  
Inventory Days Days3765 56.5%  
Debtors Days Days2829 97.5%  
Net fixed assets Rs m46835 5.5%   
Share capital Rs m123213 58.1%   
"Free" reserves Rs m7,21316,715 43.2%   
Net worth Rs m7,33616,928 43.3%   
Long term debt Rs m00-   
Total assets Rs m11,10524,162 46.0%  
Interest coverage x29.5163.7 18.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.51.4 37.2%   
Return on assets %7.616.8 45.1%  
Return on equity %10.723.7 45.1%  
Return on capital %22.236.9 60.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m61369 16.4%   
Fx outflow Rs m3,6303,807 95.4%   
Net fx Rs m-3,570-3,438 103.8%   
CASH FLOW
From Operations Rs m1,6101,527 105.4%  
From Investments Rs m687-2,148 -32.0%  
From Financial Activity Rs m-2,677-1,024 261.3%  
Net Cashflow Rs m-380-1,646 23.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 2.0 7.9 25.3%  
FIIs % 1.6 0.1 1,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 17.1 125.7%  
Shareholders   41,647 18,270 228.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALEMBIC LTD  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Sep 20, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS